CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 681 - 690 of 730
Study Number Lead Group Study Title CIRB Study Status
S1505 SWOG A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma Adult CIRB - Late Phase Emphasis Available to Open
S1507 SWOG A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies Adult CIRB - Late Phase Emphasis Available to Open
S1512 SWOG A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) Adult CIRB - Late Phase Emphasis Available to Open
S1513 SWOG Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1600 SWOG A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes Cancer Prevention and Control CIRB Available to Open
S1602 SWOG A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Nave High-Grade Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1605 SWOG Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1607 SWOG A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy Adult CIRB - Late Phase Emphasis Available to Open
S1608 SWOG Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma Adult CIRB - Late Phase Emphasis Available to Open
S1609 SWOG DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Adult CIRB - Late Phase Emphasis Available to Open
Displaying 681 - 690 of 730